23.7 C
New York
Tuesday, June 2, 2026

Tag: injury

Toyota’s Collaborative Safety Research Center Touts Partnerships, Eyes Future with Announcement of 10 New Projects

New research projects focus on behavioral safety, crash prevention and passive safetyANN ARBOR, Mich., June 2, 2026 /PRNewswire/ -- Before joining Toyota's Collaborative Safety Research Center (CSRC), Zhaonan Sun spent years...

Dallas Firm Hamilton Wingo Files Wrongful Death Lawsuit in Oak Cliff Apartment Building Explosion, Fire

DALLAS, June 1, 2026 /PRNewswire/ -- The nationally recognized plaintiffs' attorneys from Dallas' Hamilton Wingo have filed the first wrongful death lawsuit resulting from...

BestQool Announces Summer Promotion and Fall Refresh with New Logo and BQ60Pro Preview

Summer Appreciation Sales Offers 12% Off All Products NEW YORK, Aug. 15, 2025 /PRNewswire/ -- BestQool , a pioneer manufacturer of home-use red light therapy...

Regen BioPharma Discusses Potential Impact of HemaXellerate on Chemotherapy Treament Market

SAN DIEGO, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Regen BioPharma, Inc. (OTC ID: RGBP and RGBPP) today provided further insight into its planned Phase 1 clinical trial of HemaXellerate, the company’s innovative stem cell-derived therapy, which has already received U.S. FDA clearance. While the initial focus is on treating aplastic anemia, a rare orphan indication, Regen BioPharma is evaluating expanded applications for this groundbreaking therapy in markets poised for significant growth.

Precigen Announces Full FDA Approval of PAPZIMEOS (zopapogene imadenovec-drba), the First and Only Approved Therapy for the Treatment of Adults with Recurrent Respiratory Papillomatosis

PAPZIMEOS approval marks a historic milestone for the RRP patient community as the first and only FDA-approved therapy for the treatment of adults with...

Akero Therapeutics Announces Lancet Publication of the Phase 2b HARMONY Clinical Trial Demonstrating 96 Weeks Treatment with EFX Reduced Liver Fibrosis in Patients with...

Results support potential of efruxifermin (EFX) to reduce risk of fibrosis progression in patients with pre-cirrhotic (F2-F3) MASH
Results support potential of efruxifermin (EFX) to reduce risk of fibrosis progression in patients with pre-cirrhotic (F2-F3) MASH

G Mining Ventures Reports Strong Q2 2025 Results

BROSSARD, QC, Aug. 14, 2025 /PRNewswire/ - G Mining Ventures Corp. ("GMIN" or the "Corporation") (TSX: GMIN) (OTCQX: GMINF) is pleased to report its...

CPSC Warns Consumers to Immediately Stop Using 10-Inch Elitespace Hybrid Mattresses Due to Risk of Serious Injury or Death from Fire; Violates Mandatory Standard...

WASHINGTON, Aug. 14, 2025 /PRNewswire/ -- The U.S. Consumer Product Safety Commission (CPSC) is warning consumers to immediately stop using Elitespace Hybrid Mattresses. The...

Normet Group: Record high quarterly order intake, profitability weighed down by lower deliveries and currency effect

HELSINKI, Aug. 14, 2025 /PRNewswire/ -- Normet Group has published its Half-year Financial Report for 1 January-30 June 2025 on 14 August 2025. Below...

Normet Group: Record high quarterly order intake, profitability weighed down by lower deliveries and currency effect

HELSINKI, Aug. 14, 2025 /PRNewswire/ -- Normet Group has published its Half-year Financial Report for 1 January-30 June 2025 on 14 August 2025. Below...

Mountain Province Diamonds Announces Second Quarter Financial Results for 2025

TSX: MPVD TORONTO, Aug. 12, 2025 /CNW/ - Mountain Province Diamonds Inc. ("Mountain Province", the "Company") (TSX: MPVD) today announces financial results for the second quarter...

Mountain Province Diamonds Announces Second Quarter Financial Results for 2025

TSX: MPVD TORONTO, Aug. 12, 2025 /PRNewswire/ - Mountain Province Diamonds Inc. ("Mountain Province", the "Company") (TSX: MPVD) today announces financial results for the second quarter...

Mountain Province Diamonds Announces Second Quarter Financial Results for 2025

TSX: MPVD TORONTO, Aug. 12, 2025 /PRNewswire/ -- Mountain Province Diamonds Inc. ("Mountain Province", the "Company") (TSX: MPVD) today announces financial results for the second quarter...

XORTX Completes USD $114,500 Private Placement

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES
OR FOR DISSEMINATION IN THE UNITED STATES

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsInjury